Study affirms metformin as first-line treatment

Type 2 diabetes patients treated with metformin live slightly longer on average than people without the condition, according to a large observational study that backs the drug as a safe first-line treatment.

"What we found was illuminating," says lead author Professor Craig Currie from Cardiff University's School of Medicine, whose study compares the longevity of patients taking metformin with the general population as well as those treated with sulphonylureas (SUs).

Patients treated with metformin had a